Session Information
Date: Monday, June 5, 2017
Session Title: Parkinson's Disease: Non-Motor Symptoms
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: To collect details of linguistic validations and translations of the non-motor symptoms questionnaire (NMSQuest) and non-motor symptoms scale (NMSScale) globally.
Background: The patient completed Parkinson’s disease (PD) NMSQuest and the health-professional completed NMSScale were validated since 2006 and recommended by the MDS and other learned societies for holistic assessment of NMS and their burden. The global range of these tools have not been properly evaluated.
Methods: A specific protocol was developed for a global survey involving relevant members of the MDS Non-Motor-Parkinson’s disease-Trainee Junior Subgroup . All reviewed literature, conducted interviews with international collaborators and Mapi was contacted (http://mapigroup.com/) to capture available translations of the NMSQuest and NMSScale.
Results: Translations of NMSQuest were available using linguistic validation in Dutch, French, German, Greek, Italian, Japanese, Malay, Chinese (mandarin), Spanish and Swedish. Investigator translated use of NMSQuest was reported from Thailand, India and Brazil.
The NMSScale underwent linguistic validation in Danish, French, German, Italian, Norwegian, Spanish and Swedish. Translated use was reported in Malay, Chinese, Arabic and Brazilian (Portuguese). NMSScale has been used as an outcome measure in several industry-sponsored clinical trials (e.g. Abbvie, Britannia, Lundbeck, Pfizer, Cynapsus, UCB among others). Translations for oral administration of both tools are reported from Arab states, Korea, Egypt, India, Turkey, Taiwan, Tanzania, Nigeria and Mali.
Conclusions: The use of NMSQuest as a flagging tool and NMSScale as a grading holistic measure of NMS in PD indicates the global reach of these instruments which should be regarded as an essential quality standard for assessment of PD in clinic. Furthermore, they should be routinely included in relevant clinical trials and as such it is crucial that these tools are properly validated in different languages.
References: Acknowledgement
Non-Motor-Parkinson’s disease-Trainee Junior Subgroup thanks Prof K Ray Chaudhuri and the NM-PD-SG.
To cite this abstract in AMA style:
A. Sauerbier, L. Klingelhoefer, R. Banerjee, S. Diaconu, R. Erro, T. Farombi, S. Gangadharan, A. Macerollo, L. Chahine, O. Jitkritsadakul, R. Biundo, M. Grilo, H. Dafsari, G. Pagano, F. Niccolini, N. Titova. A global survey of the use and linguistic translation of the NMSQuest and NMSScale: implications for non-motor studies in Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/a-global-survey-of-the-use-and-linguistic-translation-of-the-nmsquest-and-nmsscale-implications-for-non-motor-studies-in-parkinsons-disease/. Accessed June 14, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/a-global-survey-of-the-use-and-linguistic-translation-of-the-nmsquest-and-nmsscale-implications-for-non-motor-studies-in-parkinsons-disease/